Michigan is currently home to 2187 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Ann Arbor, Detroit, Grand Rapids and Kalamazoo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Goals for Epilepsy Clinic Visits Trial
Recruiting
The purpose of this project is to conduct a trial to assess whether patients that receive a tablet-based waiting room priority communication tool (the "Epilepsy Visit Planner") have improved outcomes compared to patients that do not receive the tool. The project's hypotheses are: * Patients that receive the Epilepsy Visit Planner will have improved patient-provider communication compared to the non-planner group. * Patients that receive the Epilepsy Visit Planner will have improved quality of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Drug Resistant Epilepsy
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Recruiting
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/29/2024
Locations: Saint Joseph Mercy Hospital, Ann Arbor, Michigan
Conditions: Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Non-Hodgkin Lymphoma
Non-weight Bearing Exercise for Accelerated Healing of Diabetic Foot Ulcers
Recruiting
The goal of this study is to improve the therapeutic management of diabetic foot ulcers (DFU). The main questions to answer are if a program of non-weight bearing exercise helps the DFU heal faster than standard wound care. This randomized clinical trial will determine how blood flow to the ulcer and whole body metabolism may be improved with exercise. Participants will be randomized to either exercise + standard wound care or standard wound care alone and undergo testing for leg blood flow, fit... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/29/2024
Locations: School of Kinesiology, Ann Arbor, Michigan
Conditions: Type2diabetes, Foot Ulcer
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Recruiting
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with Olaparib or Niraparib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/25/2024
Locations: South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Recruiting
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Henry Ford Cancer, Detroit, Michigan
Conditions: Pancreas Neoplasm, Stomach Neoplasm, Gastrointestinal Neoplasms, Digestive System Neoplasm, Neoplasms by Site, Neoplasms
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Recruiting
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: The Cancer and Hematology Centers, Grand Rapids, Michigan
Conditions: Uveal Melanoma
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mor... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/24/2024
Locations: VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan
Conditions: Carcinoma, Hepatocellular, Cirrhosis
A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
Recruiting
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Ascension St. John Hospital, Grosse Pointe Woods, Michigan
Conditions: Multiple Myeloma
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Recruiting
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
10/23/2024
Locations: C S Mott Children's Hospital, Ann Arbor, Michigan
Conditions: Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
Recruiting
This study is designed to help patients with type 2 diabetes and their clinicians: (a) identify which glucose lowering medications have the most favorable effects on heart health and other patient-important outcomes, (b) inform the timing of medication initiation, and (c) identify whether medication benefits apply equally to all adults with type 2 diabetes, or may be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal function, or other factors.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/22/2024
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a diagnosis of Parkinson's Disease consistent with the UK Parkinson's Disease Society (UKPDS) Brain Bank diagnostic criteria, who are experiencing wearing off symptoms and levodopa-induced dyskinesia.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/21/2024
Locations: Clinical Site, Farmington Hills, Michigan
Conditions: Parkinson Disease
Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT) Multi-Site RCT
Recruiting
In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure \[PROM\] of HNC-rel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Head and Neck Cancer, Body Image Disturbance, Body Image, Survivorship, Psychosocial Impairment, Mental Health Issue